$ADVM
Adverum Biotechnologies, Inc.

2018 Q2 Form 10-Q Financial Statement

#000156459018020510 Filed on August 08, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2017 Q2
Revenue $493.0K $463.0K
YoY Change 6.48% 50.81%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.180M $4.060M
YoY Change 126.11% -20.55%
% of Gross Profit
Research & Development $11.22M $8.490M
YoY Change 32.16% 6.66%
% of Gross Profit
Depreciation & Amortization $640.0K $540.0K
YoY Change 18.52% 58.82%
% of Gross Profit
Operating Expenses $20.40M $12.56M
YoY Change 62.44% -79.81%
Operating Profit -$12.09M
YoY Change -80.46%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $1.090M $663.0K
YoY Change 64.4% 198.65%
Pretax Income -$18.81M -$11.43M
YoY Change 64.57% -81.46%
Income Tax
% Of Pretax Income
Net Earnings -$18.81M -$11.43M
YoY Change 64.57% -81.46%
Net Earnings / Revenue -3815.42% -2468.68%
Basic Earnings Per Share
Diluted Earnings Per Share -$301.6K -$265.8K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q2 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $234.9M $197.4M
YoY Change 19.0% -18.19%
Cash & Equivalents $156.4M $39.52M
Short-Term Investments $79.40M $157.9M
Other Short-Term Assets $3.000M $2.200M
YoY Change 36.36% 83.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $237.9M $199.6M
YoY Change 19.19% -18.06%
LONG-TERM ASSETS
Property, Plant & Equipment $2.500M $3.800M
YoY Change -34.21% -5.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.100M $100.0K
YoY Change 1000.0% 0.0%
Total Long-Term Assets $8.700M $9.000M
YoY Change -3.33% -56.52%
TOTAL ASSETS
Total Short-Term Assets $237.9M $199.6M
Total Long-Term Assets $8.700M $9.000M
Total Assets $246.6M $208.6M
YoY Change 18.22% -21.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.100M $1.100M
YoY Change 90.91% -54.17%
Accrued Expenses $8.400M $5.200M
YoY Change 61.54% 26.83%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.40M $8.300M
YoY Change 37.35% 5.06%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $368.0K $6.800M
YoY Change -94.59% 1.49%
Total Long-Term Liabilities $368.0K $6.800M
YoY Change -94.59% 1.49%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.40M $8.300M
Total Long-Term Liabilities $368.0K $6.800M
Total Liabilities $13.10M $16.40M
YoY Change -20.12% -1.74%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $233.4M $192.2M
YoY Change
Total Liabilities & Shareholders Equity $246.6M $208.6M
YoY Change 18.23% -21.1%

Cashflow Statement

Concept 2018 Q2 2017 Q2
OPERATING ACTIVITIES
Net Income -$18.81M -$11.43M
YoY Change 64.57% -81.46%
Depreciation, Depletion And Amortization $640.0K $540.0K
YoY Change 18.52% 58.82%
Cash From Operating Activities -$11.35M -$11.42M
YoY Change -0.61% 38.76%
INVESTING ACTIVITIES
Capital Expenditures -$160.0K -$470.0K
YoY Change -65.96% -53.47%
Acquisitions
YoY Change
Other Investing Activities $15.06M -$20.20M
YoY Change -174.55% -685.51%
Cash From Investing Activities $14.90M -$20.67M
YoY Change -172.09% -947.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 190.0K 150.0K
YoY Change 26.67% 66.67%
NET CHANGE
Cash From Operating Activities -11.35M -11.42M
Cash From Investing Activities 14.90M -20.67M
Cash From Financing Activities 190.0K 150.0K
Net Change In Cash 3.740M -31.94M
YoY Change -111.71% 460.35%
FREE CASH FLOW
Cash From Operating Activities -$11.35M -$11.42M
Capital Expenditures -$160.0K -$470.0K
Free Cash Flow -$11.19M -$10.95M
YoY Change 2.19% 51.66%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q4 us-gaap Short Term Investments
ShortTermInvestments
119966000
CY2018Q2 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1250000
CY2018Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
368000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-886000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
394000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14547000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1322000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-925000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1152000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-18810000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-11430000
CY2018Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
59000
CY2018Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
998000
CY2017Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5000000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-227000
us-gaap Profit Loss
ProfitLoss
-36010000
us-gaap Profit Loss
ProfitLoss
-27529000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
21000
us-gaap Operating Expenses
OperatingExpenses
29606000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
709000
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12053000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
925000
CY2017Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17553000
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
us-gaap Operating Income Loss
OperatingIncomeLoss
-28681000
CY2018Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
493000
CY2017Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
463000
CY2018Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
38000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
124000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
149000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
100000
us-gaap Repayments Of Debt
RepaymentsOfDebt
88000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
69985000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
342000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-231000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
85930000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-182647000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
70519000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
222170000
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
156449000
CY2017Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
39523000
us-gaap Straight Line Rent
StraightLineRent
43000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24334000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23238000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
46136000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
172788000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
86797000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
382000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
40279000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-159520000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
70188000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
342000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
936000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates<font style="font-weight:normal;">&#8212; The accompanying consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the consolidated financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, income taxes, and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</font></p></div>
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2006-07-17
dei Entity Information Date To Change Former Legal Or Registered Name
EntityInformationDateToChangeFormerLegalOrRegisteredName
2016-05-11
CY2018Q2 advm Cash And Cash Equivalent Amortized Cost
CashAndCashEquivalentAmortizedCost
148900000
CY2018Q2 advm Cash And Cash Equivalent Gross Unrealized Gain
CashAndCashEquivalentGrossUnrealizedGain
0
CY2018Q2 advm Cash And Cash Equivalent Gross Unrealized Loss
CashAndCashEquivalentGrossUnrealizedLoss
0
CY2018Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
148900000
CY2018Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
79531000
CY2018Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
106000
CY2018Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
79425000
CY2017Q4 advm Cash And Cash Equivalent Amortized Cost
CashAndCashEquivalentAmortizedCost
57780000
CY2017Q4 advm Cash And Cash Equivalent Gross Unrealized Gain
CashAndCashEquivalentGrossUnrealizedGain
0
CY2017Q4 advm Cash And Cash Equivalent Gross Unrealized Loss
CashAndCashEquivalentGrossUnrealizedLoss
0
CY2017Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
57780000
CY2017Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
120148000
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
183000
CY2017Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
119966000
CY2018Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2018Q2 advm Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax Temporary
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxTemporary
100000
CY2018Q2 advm Other Than Temporary Impaired Investments Available For Sale Securities
OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities
0
CY2018Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2629000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2295000
CY2018Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2368000
CY2017Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2259000
CY2018Q2 advm Accrued Preclinical Clinical And Development Process Costs
AccruedPreclinicalClinicalAndDevelopmentProcessCosts
2213000
CY2017Q4 advm Accrued Preclinical Clinical And Development Process Costs
AccruedPreclinicalClinicalAndDevelopmentProcessCosts
2165000
CY2018Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1140000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
245000
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
587000
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
3344000
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
4221000
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
4683000
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
4846000
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
33853000
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
51534000
CY2015Q3 us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
3
CY2015Q4 us-gaap Loss Contingency Number Of Defendants
LossContingencyNumberOfDefendants
2
CY2017Q1 us-gaap Loss Contingency Damages Paid Value
LossContingencyDamagesPaidValue
13000000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6695000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1589000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1489000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
518000
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6277000
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2754000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.51
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.38
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.38
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.98
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.84
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.93
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y9M18D
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
10653000
CY2018Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
5705000
CY2018Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5826000
CY2017Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2243000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9255000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4139000
CY2018Q2 advm Number Of Executives Departure
NumberOfExecutivesDeparture
2
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9000000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10300000

Files In Submission

Name View Source Status
0001564590-18-020510-index-headers.html Edgar Link pending
0001564590-18-020510-index.html Edgar Link pending
0001564590-18-020510.txt Edgar Link pending
0001564590-18-020510-xbrl.zip Edgar Link pending
advm-10q_20180630.htm Edgar Link pending
advm-20180630.xml Edgar Link completed
advm-20180630.xsd Edgar Link pending
advm-20180630_cal.xml Edgar Link unprocessable
advm-20180630_def.xml Edgar Link unprocessable
advm-20180630_lab.xml Edgar Link unprocessable
advm-20180630_pre.xml Edgar Link unprocessable
advm-ex102_101.htm Edgar Link pending
advm-ex103_100.htm Edgar Link pending
advm-ex104_24.htm Edgar Link pending
advm-ex121_6.htm Edgar Link pending
advm-ex311_9.htm Edgar Link pending
advm-ex312_7.htm Edgar Link pending
advm-ex321_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gyz3tqvqclad000001.jpg Edgar Link pending
gyz3tqvqclad000002.jpg Edgar Link pending
gyz3tqvqclad000003.jpg Edgar Link pending
gyz3tqvqclad000004.jpg Edgar Link pending
gyz3tqvqclad000005.jpg Edgar Link pending
gyz3tqvqclad000006.jpg Edgar Link pending
gyz3tqvqclad000007.jpg Edgar Link pending
gyz3tqvqclad000008.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending